Terns Pharmaceuticals, Inc.
TERN
$52.63
$0.070.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.49% | -20.17% | -2.16% | 26.94% | 20.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.35% | 11.14% | 7.23% | 7.79% | 7.86% |
| Operating Income | -6.35% | -11.14% | -7.23% | -7.79% | -7.86% |
| Income Before Tax | -6.57% | -12.37% | -5.97% | -6.93% | -3.76% |
| Income Tax Expenses | 857.50% | -25.81% | 4.92% | -9.28% | -18.37% |
| Earnings from Continuing Operations | -8.13% | -12.26% | -5.97% | -6.86% | -3.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.13% | -12.26% | -5.97% | -6.86% | -3.71% |
| EBIT | -6.35% | -11.14% | -7.23% | -7.79% | -7.86% |
| EBITDA | -6.58% | -11.46% | -7.56% | -7.92% | -7.91% |
| EPS Basic | -0.75% | 4.75% | 13.82% | 13.07% | 17.79% |
| Normalized Basic EPS | 0.67% | 4.66% | 13.82% | 12.99% | 17.77% |
| EPS Diluted | -0.75% | 4.75% | 13.82% | 13.07% | 17.79% |
| Normalized Diluted EPS | 0.67% | 4.66% | 13.82% | 12.99% | 17.77% |
| Average Basic Shares Outstanding | 7.31% | 17.84% | 22.99% | 22.95% | 26.14% |
| Average Diluted Shares Outstanding | 7.31% | 17.84% | 22.99% | 22.95% | 26.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |